Objective: The aim of the study was to investigate and evaluate the available data regarding the progression of CKD and extent of proteinuria in view of the association between CKD and cardiovascular outcomes and, furthermore, between the extent of proteinuria and its association with progression of CKD. Material and Methods: PubMed was searched using the search key words (finerenone) or (paricalcitol) AND (albuminuria). All patients with CKD, DMT2 and treatment with ACEi or ARBs were eligible. The paricalcitol study by Manson et al. was included for the comparison of cardiovascular outcomes, even though investigating a cohort without a history of cancer and major cardiovascular events without a focus on CKD, attempting to demonstrate a prophylactic effect. For methodological quality assessment, Downs and Black scale was utilized. Results: A total of seven studies, three finerenone and four paricalcitol, were included in this meta-analysis. Six of these studies were prospective, double-blind, placebo-controlled and randomized, while Mendes et al. was an observational study. Six studies included patients with CKD, DMT2 (mean duration > 14.5 years) and at least 81.65% were pretreated with ACEi or ARBs, while Manson et al. observed a cohort without CKD as mentioned above. The duration was 44-48 months for finerenone and 3-12 months for paricalcitol. UACR decreased in all finerenone and paricalcitol studies. The eGFR showed an initial decrease on finerenone over four weeks but proceeded more mildly than in the control group, while the data for paricalcitol were overall insufficient for evaluation of eGFR. The ARR on finerenone for a decrease of eGFR >57% was 5.6% and 48.7% in RRR. Very few cases were reported for paricalcitol. Hyperkalemia occurred more often on finerenone, whereas hypercalcemia occurred more often on paricalcitol. Cardiovascular adverse events occurred more often on finerenone, possibly influenced by the comparison with an inhomogeneous cohort with and without CKD. For cardiovascular events, a maximal ARR of 2.6% and a RRR of 22.03% was proven in the Fidelio study, compared to inhomogeneous reductions in paricalcitol. Overall mortality was lower in all intervention groups of both drugs compared to the control group, reducing the relative risk by maximal 10.89% (53) in finerenone and by 1.57% in paricalcitol (61). Conclusion: Both drugs positively influence the UACR and albuminuria, thus, potentially slowing down the progression of CKD. Cardiovascular morbidity and mortality are more reduced on finerenone. Estimated GFR on finerenone stabilizes after an initial dip to a slower progression. This was insufficiently investigated in paricalcitol, which leaves room for further investigation. Overall adverse effects did occur rarest in the 1 μg paricalcitol group.